Non-Small Cell Lung Cancer (NSCLC) - Dynamic Market Forecast to 2025

Non-Small Cell Lung Cancer (NSCLC) - Dynamic Market Forecast to 2025

Summary

The NSCLC therapeutics market is a rapidly evolving field in which new developments are constantly influencing the landscape. The Forecast Update is designed to help clients stay abreast of the latest news in the NSCLC space, including regulatory, commercial, and clinical events, and to understand how these events will impact the market forecast.

Scope

Key events covered in the Dynamic Market Forecast include -
- Regulatory filings
- Approval decisions
- Pricing changes
- Patent litigation
- Clinical trial data announcements
- Clinical trial failures
- Clinical trial timeline updates

Components of the slide deck include -
- Timeline of market-impacting events
- Key clinical trial landscape updates
- Detailed analysis of the most impactful events, including new primary research to gain Key Opinion Leader perspective
- Overview of updates to the forecast model based on anticipated future impact of events
- Forward-looking events calendar listing expected key updates to the NSCLC competitive space in the next quarter

Reasons to buy

- Recent regulatory events
- Recent commercial events
- Recent clinical events
- Market dynamics in the frontline NSCLC setting
- Landscape changes in the EGFR-mutant NSCLC setting
- Projected treatment algorithm shifts in the ALK-mutant NSCLC setting

1. Dynamic Market Forecast Overview 5
1.1 Related Reports 6
1.2 Upcoming Related Reports 7
2. Executive Summary 8
2.1 Key Events in Update 9-10
2.2 Updates to Treatment Algorithms 11
2.3 Clinical Trial Landscape Updates 12-13
2.4 Pipeline Landscape Updates 14
2.5 Market Insight on Key Events 15
3. Event 1: Market Dynamics Shift in Frontline NSCLC 16
3.1 Key Updates to the Frontline Non-squamous Setting 17
3.2 Merck & Co., Keytruda (pembrolizumab) 18-19
3.3 AstraZeneca, Imfinzi (durvalumab) + tremelimumab 20-21
3.4 Pfizer and Merck KGaA , Bavencio (avelumab) 22
3.5 Roche, Tecentriq (atezolizumab) 23
3.6 Novartis, Tafinlar (dabrafenib) + Mekinist (trametinib) 24
3.7 Additional Clinical Trial Updates- Frontline Setting 25-26
3.8 Summary/Trends 27
3.9 Sources 28
4. Event 2: Weak Competition in the EGFRm+ Segment Creates Opportunity for Tagrisso 29
4.1 Key Updates to the EGFRm+ Segment 30
4.2 AstraZeneca, Tagrisso (osimertinib) 31-33
4.3 Pfizer, dacomitinib 34
4.4 Additional Clinical Trial Updates- EGFRm+ Setting 35
4.5 Summary/Trends 36
4.6 Sources 37
5. Event 3: New SOC Anticipated in the ALKm+ 1L Setting 38
5.1 Key Updates to the ALKm+ Setting 39
5.2 Roche, Alecensa (alectinib) 40
5.3 Takeda, Alunbrig (brigatinib) 41
5.4 Pfizer, lorlatinib 42
5.5 Summary/Trends 43
5.6 Sources 44
6. Other Events of Interest 45
6.1 Various Developers 46-47
6.2 Sources 48
7. Dynamic Market Forecast Highlights 49
7.1 Updates to Frontline NSCLC Segment 50
7.2 Updates to EGFRm+ NSCLC Segment 51
7.3 Updates to ALKm+ NSCLC Segment 52
7.4 Selected Additional Forecast Updates 53
8. Events Calendar 54
8.1 Key Clinical Events Expected in Q4 2017 55-56
9. Appendix 57
9.1 Methodology 58
9.2 Primary Research 59-60
9.3 About the Authors 61-62
9.4 About GlobalData 63
9.5 Contact Us 64
9.6 Disclaimer 65


Squamous Non-Small Cell Lung Carcinoma (Oncology) - Drugs in Development, 2021

Squamous Non-Small Cell Lung Carcinoma (Oncology) - Drugs in Development, 2021Squamous Non-Small Cell Lung Carcinoma (Oncology) - Drugs in Development, 2021 provides an overview of the Squamous Non-Small Cell Lung

USD 2000 View Report

Squamous Non-Small Cell Lung Cancer (Oncology) - Drugs in Development, 2021

Squamous Non-Small Cell Lung Cancer (Oncology) - Drugs in Development, 2021Squamous Non-Small Cell Lung Cancer (Oncology) - Drugs in Development, 2021 provides an overview of the Squamous Non-Small Cell Lung

USD 2500 View Report

Global Non-Small Cell Lung Cancer Therapeutics Market Research Report

Non-Small Cell Lung Cancer (NSCLC) is the most common cancer and the leading cause of cancer-related mortality globally. In the context of China-US trade war and COVID-19 epidemic, it will

USD View Report

Small Cell Lung Cancer - Opportunity Analysis and Forecasts to 2029

Small Cell Lung Cancer - Opportunity Analysis and Forecasts to 2029Lung cancer remains a leading cause of cancer-related death worldwide and is a huge global health burden. Small cell lung

USD 10995 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available